Protein−protein interactions play a central role in cellular function. Improving the understanding of complex formation has many practical applications, including the rational design of new therapeutic agents and the mechanisms governing signal transduction networks. The generally large, flat, and relatively featureless binding sites of protein complexes pose many challenges for drug design. Fragment docking and direct coupling analysis are used in an integrated computational method to estimate druggable protein−protein interfaces. (i) This method explores the binding of fragment-sized molecular probes on the protein surface using a molecular dockingbased screen. (ii) The energetically favorable binding sites of the probes, called hot spots, are spatially clustered to map out candidate binding sites on the protein surface. (iii) A coevolution-based interface interaction score is used to discriminate between different candidate binding sites, yielding potential interfacial targets for therapeutic drug design. This approach is validated for important, well-studied disease-related proteins with known pharmaceutical targets, and also identifies targets that have yet to be studied. Moreover, therapeutic agents are proposed by chemically connecting the fragments that are strongly bound to the hot spots.
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protein−protein interface | druggable surface | hot spots | direct coupling analysis | drug design P rotein−protein interactions (PPIs) mediate a wide range of important cellular functions, including signal transduction and enzymatic processes. The regulation of these interactions has drawn intense focus in physiology and pathology, where PPI interfaces have emerged as a new class of molecular targets for pharmacological intervention (1, 2) . The design of drugs to target PPIs, however, faces numerous challenges (3) . Although over 41,000 unique human protein interactions have been experimentally discovered and reported on Human Protein Reference Database (4), only ∼2,500 nonredundant multiprotein complexes have experimentally determined structures available in the Protein Data Bank (5) . Therefore, the current experimental methods cannot accommodate the high demand for structural details of these interactions. Even when the structural complexes are known, targeting PPIs with small molecules poses a significant challenge. Many protein interfaces have large, featureless surfaces that lack obvious small-molecule binding pockets, making it difficult to design drugs with the ability to modulate (inhibit or stabilize) the PPIs with the necessary selectivity and potency (6) .
In the past two decades, two major classes of computational methods for protein−protein interface prediction have emerged (7) : (i) data-driven methods (8) (9) (10) (11) (12) (13) and (ii) molecular docking methods (14) . Data-driven methods include homology modeling (8, 9) , machine learning (10) , and coevolution-based statistical models (11) (12) (13) . These approaches make predictions using homologous data as templates or by extracting interaction patterns from data using statistical models. On the other hand, molecular docking approaches (14) search for putative binding modes with favorable interaction energies and surface complementarity by using physics-based or geometric models. Although the datadriven methods are predictive, they are often limited by the amount of data that is available to train a statistical model. Docking methods can make structural predictions at atomic-level detail, but they are limited by the high-dimensional complexity of performing conformational searches as well as the accuracy of the force field being used. The predictive capabilities of docking approaches can be improved by incorporating relevant information (e.g., amino acid coevolution) (15) , which can be extracted from the existing wealth of sequence data. Hence, data-driven methods can be combined with physics-based docking approaches to improve their predictive power. To overcome these challenges, an integrated computational approach called fragment docking and direct coupling analysis (Fd-DCA) is developed by combining a docking methodology with coevolutionary signals from sequence data. This approach offers a distinct direction toward identifying PPI-mediated biological functions as well as the development of therapeutic agents that target protein interactions.
Druggable Interface Identification Design Framework
To identify druggable surfaces, one needs to find the residues or epitopes in the proteins that are responsible for the majority of Significance Protein−protein interfaces have become an emerging class of molecular targets for the design of therapeutic drugs. However, major challenges exist for the correct identification of binding sites on the protein surface as well as drug-like modulators of protein−protein interaction. An integrated approach using molecular fragment docking and coevolutionary analysis is presented to face these challenges. This approach can accurately predict and characterize the binding sites for protein−protein interactions as well as provide clusters of bound, fragment-sized molecules on the druggable regions of the predicted binding site. These bound, molecular fragments can be chemically combined to create candidate drugs.
the binding affinity between proteins or between a protein and a ligand. These regions are commonly called "hot spots" (16) . The design of therapeutic agents that interact with hot spots has proven to be a valid methodology for inferring PPI (1). Computationally differentiating hot spots from other regions on a protein surface remains a difficult challenge (17) . Overcoming these difficulties is the main focus of this work.
One computational framework that has successfully been applied to find hot spots on protein surfaces is called FTMap (18, 19) . FTMap is a solvent mapping-based approach that explores the binding of 16 small organic molecular probes to the surface of a protein. This method first places the probes in a dense grid around the protein. An empirical free energy is then used as a scoring function to minimize each probe and find strongly bound probe configurations on the protein surface. Regions that bind clusters of multiple probe types are recognized as the hot spots of a protein. However, this process presents several challenges. First, the current probes implemented in FTMap are small organic molecules, which are only appropriate for determining druggable sites for conventional drug design. These fragments may not be appropriate for identifying the binding sites for peptide drugs as well as nonligand-bound PPI interfaces. Second, FTMap relies on a two-step downhill energy minimization to locate the binding mode for each probe, which may unexpectedly neglect binding modes that involve conformational rearrangement.
To overcome these challenges, a hot spot identification method is introduced in this work. The binding of probes on a protein surface is now performed using 31 probe molecules, which include 15 amino acid side chain residues in addition to 16 small organic molecules (SI Appendix, Fig. S1 ). Not only can this method be used to detect ligand−protein binding hot spots, but it also reveals protein/ peptide−protein interacting regions (SI Appendix). Moreover, this hot spot identification method uses the in-house molecular docking tool iFitDock (20) , which features an accurate method for estimating binding affinity (i.e., Molecular Mechanics−Generalized Born Surface Area) as well as a robust binding conformation search algorithm. These improvements allow the method to globally search for energetically favorable binding positions to generate more reliable bound conformations of the probes (details in SI Appendix).
To ensure that the hot spot predictions capture the true PPIforming surface of a protein, one can discriminate between different hot spots based on the evolutionary signature of PPI found in amino acid sequence data. The association of interacting proteins is often, in part, mediated by the unique recognition patterns on their complementary binding surfaces. These amino acid patterns arise from the constraint to maintain important amino acid complementarity over the course of natural selection (21), e.g., residues that form native contacts. Thus, coevolutionary patterns in protein sequence data can be used to identify functional complex interfaces. Extracting this rich information has been an area of great focus (12, 13, 22) , particularly with the advancement of sequencing technologies over the recent decades (23) .
Recently, DCA (24) (25) (26) has allowed for the quantification of amino acid coevolution from multiple sequence alignments of protein families or interacting protein families. DCA has successfully been used to find highly coevolved pairs of residues, which are intraprotein (24, 27) and interprotein amino acid (12, 24, 25, 28, 29) contacts. Remarkably, DCA also captures the residue contacts that stabilize functionally important conformational transitions (30) . DCA has also been applied to study specificity in bacterial signaling systems, quantifying the effect of mutations on phosphotransfer in a signaling network (29, 31) .
Preliminary results demonstrated the complementary role of DCA in the prediction of drug targets for treating human breast cancer (22, 32) . Earlier work used DCA and FTmap to predict the binding interface between the nutrient-deprivation autophagy factor-1 (NAF-1) and the B-cell lymphoma-2 (Bcl-2), as well as discover a NAF-1 small molecular binder, MAD-28, which may disrupt NAF-1/Bcl-2 binding. Motivated by these findings, this current work introduces a generalized computational approach that combines a hot spot identification method and coevolutionary analysis using DCA to find binding sites for PPI that are potential drug targets. The basic idea behind this integrated approach consists of a molecular docking-based search of candidate binding sites followed by a DCA-based discrimination of evolutionarily relevant candidates. The computational scheme consists of three steps: (i) The surface of a target protein is globally screened for the binding of 31 probe molecules using iFitDock (20) to find hot spots. (ii) The adjacent hot spots are spatially clustered to obtain candidate binding sites on the surface of a protein. (iii) A coevolutionary interface interaction score (Eq. 1) is used to discriminate between the candidate binding sites to find the most promising candidates, which demonstrate functional interactions that can potentially be targets for therapeutics.
To demonstrate the power of this integrated approach in predicting functionally relevant protein−protein binding sites, six important pharmaceutical protein−protein targets are analyzed in this study. Furthermore, the bound molecular probes identified in the hot spot search are compared directly with known drugs for those targets, showing the potential for creating novel drugs by chemically connecting the probes.
Results
Most of the potential PPI targets for drug design do not have a known complex structure. The power of the integrated approach introduced in this work is that it does not require a known complex structure for the identification of the druggable interface of a protein. To validate this integrated approach, the druggable interface is determined for six different, well-studied PPIs that are related to several diseases. For comparison purposes, this analysis is restricted to PPI systems for which the oligomeric structure is experimentally solved and there exists sufficient amino acid sequence diversity (>1,000 sequences for each family of proteins). The systems are the HIV-1 protease homodimer, human murine double minute 2 homolog (MDM2) homodimer, tumor necrosis factor-alpha (TNF-α) homotrimer, cyclin-dependent kinase 1(CDK1)−cyclin-dependent kinases regulatory subunit 1(CKS1), histone deacetylate 1(HDAC1)-metastasis-associated protein MTA1 and B-cell lymphoma 2 (Bcl-2)−Bcl-2 homologous antagonist/killer (BAK) (described in SI Appendix).
Identification of a Druggable Interface for HIV-1 Protease Homodimer.
HIV-1 protease is a symmetrical homodimer, which plays an essential role in the proper assembly and maturation of infectious virions during the HIV life cycle (33, 34) . A common strategy for designing drugs to block the spread of HIV is to target its dimerization interface, thereby preventing the assembly of the inactive monomers into an active homodimer (34) . In this case, however, there are two structural interfaces: a terminal interface and an active site interface, which are both involved in HIV-1 protease dimerization (35) .
The molecular screening of the unliganded HIV-1 protease monomer structure [Protein Data Bank (PDB) ID 3PHV] yielded two relatively large, candidate binding sites, which are denoted as site 1 and site 2 (Fig. 1A, Middle) . Site 1 covers a large portion of the protein surface, including the flap domain, active site, and the terminal domain (Fig. 1A) . The smaller site 2 is mainly located on the core domain of the protein. Accordingly, dimerization of HIV-1 protease could occur between two monomers at different interfacial combinations, e.g., site 1 to site 1, site 1 to site 2, or site 2 to site 2, respectively. Assessing the coevolutionary interface interaction score, S Interface AB (Eq. 1), for each of the combinations of candidate binding sites (Fig. 1A, Right) indicates that the strongest coevolution occurs in site 1 to site 1. This is in agreement with the crystal structure of the HIV-1 protease homodimer (PDB ID 3R0Y). The residue composition of the site 1 is shown in SI Appendix, Table S1 . Furthermore, homodimeric systems such as HIV-1 protease contain intramonomer as well as intermonomer residue pairs that coevolve. If one were to focus on coevolution exclusively between residues that lead to dimerization (i.e., exclude intramonomer coevolution), the contrast between the interaction score for site 1 to site 1 and the other combinations is more significant (as shown in SI Appendix, Fig. S2 ). Fig. 1B shows the predicted top 50 coevolving pairs of intermonomer residues across the obtained binding sites of the HIV-1 protease homodimer, i.e., site 1 to site 1. The top coevolving pairs of residues are consistent with the dimerization contacts observed in the homodimer of HIV-1 protease (PDB ID 3R0Y). These coevolving residue pairs include the flap domains, which are relatively flexible and act as a couple of gatekeepers to control substrate or ligand access to the active site.
A Strategy for Drug Design: HIV-1 Protease Homodimer. A combination of the fragment (probe) binding and coevolutionary analysis indicates that site 1 is the best target for the design of inhibitory drugs. The small molecules in site 1 (i.e., "Probe" cluster 1) could potentially be used to create a drug molecule through chemical linking. To test the plausibility of such a strategy, the probes in cluster 1 are compared with the known HIV-1 protease inhibitors (drugs) (SI Appendix, Fig.  S3 ). So far, almost all of the inhibitors have been designed to target against the formation of the active site interface (site 1/site 1). Fig. 1C shows the binding of two example inhibitors on site 1: Tipranavir (from PDB ID 3SPK) and tripeptide (from PDB ID 1A30).
Probe cluster 1 (site 1) contained the bound conformations of the 30 molecular probe types with the exception of tyrosine (Fig. 1A, Left) . By superimposing the native binding conformation of Tipranavir and tripeptide on Probe cluster 1 (Fig. 2) , it is observed that the bound probes are consistent with the moieties of the drug molecules, i.e., benzene, phenylalanine, acetone, and dimethyl ether are found on the corresponding binding sites. The results imply that the integrated approach is sufficiently robust to detect druggable sites and identify appropriate molecular fragments that can bind to those sites. These fragments can be used to assemble drugs according to combinatorial principles by linking or decorating a given scaffold. It should be noted that, although the probe types are consistent with the side chains of Tipranavir and tripeptide, they appear bound in several additional conformations not observed in the PDB structures of 3SPK and 1A30; this can be attributed to the lack of chemical bonds (e.g., a backbone) linking the fragments, which would act as an additional constraint in the free energy minimization. Additionally, similar results are obtained from the superimposition of the HIV-1 protease substrate p2/NC on the Probe cluster 1 (SI Appendix, Fig. S4) . These results open the door for designing substrate-competitive peptide drugs by mutating the residues of the substrate to the ones that are predicted by fragment docking to have stronger binding affinities.
Although the binding sites of Tipranavir and a tripeptide are located on site 1, additional hot spot regions that are adjacent on site 1 may also be potential drug targets (Fig. 1C and SI Appendix,  Fig. S3 ). These regions have not yet been targeted for drug design. One region is located on the terminal domain and comprises the residues of R8, P9, L24, L25, N25, and T26. The other region is located on the flap domain and comprises the residues of I47, V54, and P79. Further analysis of these adjacent regions would shed light on their potential as drug targets.
Identifying the Druggable Interface for MDM2 Homodimer and TNF-α
Homotrimer. Similar results were obtained for proteins MDM2 and TNF-α (Fig. 3) . Here, concise interpretations of the results for each are presented with detailed description in SI Appendix. The MDM2/MDMX complex has been considered as a potential target for cancer therapies (36) . The structure of the unliganded MDM2 was screened using the 31 molecular fragments, revealing two candidate binding sites (Fig. 3A) . The highest interface interaction score, S Interface AB (Eq. 1), was observed between the homodimerization interface formed by site 1 of two monomers (SI Appendix, Fig. S5 ), and the residues on site 1 is listed in SI Appendix, Table S1 . The predicted homodimeric interface is in agreement with the crystal structure of the homodimer (PDB ID 3VBG). Additionally, the molecular probes are found to bind to the small druggable cavity formed by residues of Q71, Q72, H73, and V93 ( Fig. 3B and SI Appendix, Fig. S6 ). This predicted druggable cavity is distinct from the binding site of the inhibitors shown in Fig. 3B , thus providing a future direction for MDM2 inhibitor optimization.
Biological agents targeting TNF-α, to promote disassembly of its homotrimerization, have been licensed for treating a variety of inflammatory conditions (37) . A monomer structure was isolated from the homotrimer complex of TNF-α (PDB ID 1TNF) as the starting structure for the binding site search. Two main candidate binding sites were found during the molecular screening (Fig. 3C) , Fig. S5 ). The top 50 coevolving residue pairs given by DI (Eq. 2) are plotted on a contact map (orange dots) with the intermonomer (magenta circles) and intramonomer (light blue circles) contacts from the experimental structure (PDB ID 1TNF). (D) The experimentally known destabilizer of TNF-α targets the predicted site 1 to interfere in the homotrimer formation (green stick model is a small molecule destabilizer, and yellow cartoon model is the peptide destabilizer M21) is shown. An additional region on site 1 that is predicted to have potential for drug design (circled with red dash lines) is also shown.
of which, coevolutionary analysis indicates that the TNF-α assembles via site 1 to site 1 (SI Appendix, Fig. S7 ). The residues on site 1 are listed in SI Appendix, Table S1 . Looking at where the probes bind on TNF-α, it is observed that Probe cluster 1 corresponds to the binding target of both known inhibitors. However, these existing inhibitors only occupy approximately one-quarter of the identified druggable binding region on site 1 and prevent the formation of the trimer from the dimer (as shown in SI Appendix, Fig. S8 ). This suggests that more effective inhibitors may be designed that bridge the three discovered binding regions of site 1 (Fig. 3D and SI Appendix, Fig. S9 ).
Elucidating a Druggable Interface for the CDK1−CKS1 Heterodimer.
The CDK1-CKS1 complex is recruited to multiple coding regions in the genome and is necessary for the efficient expression of a significant subset of genes (38) . Recently, the CDK1-CKS1 complex was crystallized with four CDK1-CKS1 heterodimers in the asymmetric unit (39) . This structure revealed that the C lobe of the CDK1 interacts with two CKS1 proteins at their N lobe. Overexpression of CDK1 or CKS1 is strongly associated with aggressive breast tumor, and studies suggest that inhibition of CDK1 or CKS1 abrogation could be an effective treatment strategy for cancer (40, 41) .
Hot spot searches were separately performed on the isolated structures of CDK1 and CKS1, obtained from the crystal structure of the complex (PDB ID 4YC6; no monomeric structures available). The results of these searches for CDK1 and CKS1 are shown in Fig. 4A . Four different candidate binding sites with diverse shapes and sizes were found on the surface of CDK1, and three candidate binding sites were found on CKS1. The three candidate binding sites on CKS1 almost span the entire surface of CKS1. Assessing the coevolutionary interface interaction score, S Interface AB (Eq. 1), among the combinations of the candidate binding sites between CDK1 and CKS1 reveals two highly coevolving interfaces, i.e., site 1 of CDK1 to site 2 of CKS1 and site 2 of CDK1 to site 1 of CKS1 (Fig. 4A, Right) . These highly coevolving interfaces suggest that CDK1 may interact with two CKS1 at the two different binding sites (residues are shown in SI Appendix, Table S1 ), which is consistent with a previous structural study (39) . Remarkably, the interface interaction score for site 2 of CDK1 to site 1 of CKS1 is much stronger than the one for site 1 of CDK1 to site 2 of CKS1. The higher interaction score suggests that the binding of CDK1 (site 2) to CKS1 (site 1) may be functionally more important. As shown in Fig. 4C , the cleft in site 2 of CDK1 is the ATP-binding site (active site), which was also shown to bind to the ATP competitive inhibitor (from PDB ID 5HQ0). The top 50 coevolving interprotein residue pairs are plotted on a contact map for both interfaces (Fig. 4B) , further illustrating the coevolution between residue pairs that preserve those interfaces.
Prediction of the Druggable Interface for the HDAC1-MTA1 Heterodimer.
MTA1 has been regarded as a molecule that potentially plays an important role in tumor invasion and metastasis by interacting with histone deacetylates (HDACs), particularly with its family member HDAC1 (42) . Inhibiting the interaction of HDAC1 and MTA1 has been proposed as a novel strategy to overcome the metastasis of pancreatic cancer. Some inhibitors, such as metallofullerenol Gd@C 82 (OH) 22 (43) , have been developed with this strategy in mind. However, the druggable binding site on the interface remains elusive. This study provides a plausible druggable site for this molecular complex.
Searching the monomer structures of HDAC1 and MTA1 (isolated from their complex structure with PDB ID 4BKX; monomer structures are unavailable) for hot spots yielded three candidate binding sites for HDAC1 and only one large arch-shaped binding site for MTA1 (Fig. 5A) . Assessing the interface interaction score, S Interface AB (Eq. 1), between these possible interfaces indicates that MTA1 may wrap over HDAC1 on the candidate binding site 1 (Fig.  5A , Right) (residue compositions on the interfaces are shown in SI Appendix, Table S1 ). This predicted interface is consistent with the crystal structure of the complex HDAC1-MTA1 (PDB ID 4BKX). The top 50 coevolving residue pairs across site 1 of MTA1 and site 1 of HDAC1 are shown with orange sticks in the complex structure and highlighted as orange dots on the native contact map of HDAC1-MTA1 (Fig. 5B) . Fig. 5B illustrates that DCA did not reveal the contacts between the residues around 165 to 220 of MTA1 and the residues 140 to 190 of HDAC1, suggesting these regions are conserved. This is confirmed by the position-specific patterns of conservation in multiple sequence alignments (SI Appendix, Fig. S10) . Additionally, the overlap between the hot spot residues and the strongly coevolving residue pairs indicates that the region of HDAC1, shown in Fig. 5C , may be the ideal site for which to design a destabilizer.
Comparison of Prediction Accuracy with State-of-the-Art Interface
Inference Methods. The ability of Fd-DCA to predict interfacial amino acids is compared with other available state-of-the-art resources ( Table 1 ). The surface residues identified by fragment docking and enriched by the coevolutionary score on the identified protein−protein binding sites are taken as the predicted interfacial residues of Fd-DCA (see SI Appendix, Table S1 ). The performance is assessed on the validated targets discussed in the Results section, excluding the BAK−BCl2 complex for which the complete crystal structure is currently unavailable. The quality of predictions was evaluated by using the statistical measures used by Maheshwari and Brylinski (44) , i.e., accuracy (ACC), precision (PPV), sensitivity (also true positive rate, TPR), specificity (SPC), false positive rate (FPR), and Matthew's correlation coefficient (MCC). The detailed equations for these measures are described in SI Appendix.
With respect to the ACC and PPV, Fd-DCA yields higher values (0.882 and 0.672), whereas other methods, except for ConSurf (0.413 and 0.231), give values ranging from 0.7 to 0.8 and from 0.4 to 0.6. In particular, Fd-DCA presents the highest , and InterProSurf. However, PPV, TPR, SPC, and FPR only measure partial aspects of performance and do not provide a global picture of prediction performance (45) . To this end, MCC is a more balanced, comprehensive measure that considers true/false positive and true/false negative aspects together, for which Fd-DCA largely outperforms all other methods, with a value of 0.838 versus 0.087 to 0.324. In summary, the performance of Fd-DCA in predicting interfacial residues compares favorably to other related approaches.
Discussion
Fd-DCA is introduced to surmount the computational difficulties of finding druggable protein−protein interfaces. It combines an accurate hot spot prediction methodology with clues from evolutionary signatures of PPIs (i.e., coevolution) to discriminate between different hot spots. Hot spots that are found to coevolve are deduced to form the PPI interface, which are the most likely targets for drug design. The incorporation of DCA is a key factor leading to the success of the proposed method, establishing a link between candidate binding sites and PPI interfaces. It also shows that identifying candidate binding sites by using fragment docking is essential to discriminate true positive coevolutionary signals from false positive ones (SI Appendix, Fig. S13 ), therefore improving the estimation of protein−protein interfacial residue pairs. Because DCA targets covariant regions, then, in some cases, this methodology could miss very highly conserved regions. The present methodology is seen as a relevant complement to the typical and straightforward analysis of conservation. This study highlights the importance of such coevolving regions, because they are not picked up by methods that assume site independence. However, it would be valuable and straightforward to include a metric of conservation in our score. Otherwise, additional clues, such as shape complementarity of the pair of sites, could also be helpful for binding site selection. Additionally, an important feature of this approach is that no structural information about the protein complex is necessary for the identification of a druggable interface. This is especially relevant because structural data only exist for a small fraction of known PPIs.
Fd-DCA can also be used to characterize the types of small molecular fragments and their binding orientations that can mimic the binding interaction between the protein and its binding partners. Therefore, Fd-DCA can potentially be an important tool for the development of small-molecule or peptide agents for competitive binding, complementing the experimental approaches to drug design. In particular, it is now possible to perform de novo drug design and create small molecules or peptides by following the fragment-based drug discovery concept (54); this entails expanding or linking these fragment-sized probes with chemical bonds for small molecules, or peptide bonds and alanine for peptides (SI Appendix, Fig. S14) . Hence, the bound probes can act as core moieties to generate new drug leads.
Methods
The computational method, Fd-DCA, developed in this study consists of three steps (details in SI Appendix). (i) The in-house molecular docking method iFitDock (20) is used to globally explore the protein surface using 31 small-fragment-sized probe molecules (SI Appendix, Fig. S1 ). Hot spots are identified by spatially clustering the probes bound to the surface of the protein using the algorithm DI ij is the Direct Information (DI) metric (24) , which quantifies the amount of coevolutionary information (in nats) in the inferred DCA pair distribution P ðDCAÞ ij between residues i and j. Eq. 1 sums the DI terms for all pairs of residues, i and j, where i belongs to binding site A [i.e., δði ∈ AÞ] and j belongs to binding site B [i.e., δði ∈ BÞ]. Furthermore, each position in a protein, i or j, has q = 21 possible states, representing the 20 amino acids and multiple sequence alignment gap. cons-PPISP, consensus protein-protein interaction site predictor; ConSurf, conservation surface-mapping; InterProSurf, protein-protein interaction server; PIER, protein interface recognition for structural proteomics; SPPIDER, solvent accessibility-based protein-protein interaction sites identification and recognition; VORFFIR, Voronoi random forest feedback interface predictor.
